ALK2 and JAK2 Inhibition for Improved Treatment of Anemia in Myelofibrosis Patients: Preclinical Profile of an ALK2 Inhibitor Zilurgisertib in Combination with Ruxolitinib-MedSci.cn

ALK2 and JAK2 Inhibition for Improved Treatment of Anemia in Myelofibrosis Patients: Preclinical Profile of an ALK2 Inhibitor Zilurgisertib in Combination with Ruxolitinib

Stubbs, MC; Pusey, M; Wen, XM; Drake, K; Zolotarjova, N; Smith, A; Covington, M; Zhang, GF; Macarrón, R; Kim, S

BLOOD, 2023; 142 ():

科室
- - 订阅+
  - 更多科室
工具
服务